Medicare GLP-1 Coverage 2026: Everything You Need to Know

What Is the Medicare GLP-1 Bridge Program?

On March 5, 2025, CMS (Centers for Medicare & Medicaid Services) announced the Medicare GLP-1 Bridge program — a historic initiative that will provide Medicare Part D coverage for anti-obesity GLP-1 medications for the first time.¹ The program is set to launch on July 1, 2026, and will run through December 31, 2026.

This represents a massive shift in federal health policy. Until now, Medicare has been legally prohibited from covering drugs prescribed solely for weight loss under the Social Security Act. The TREAT Obesity Act, which was included in the bipartisan budget agreement signed in late 2025, amended this prohibition and directed CMS to establish a transitional coverage program.²

The Bridge program is designed as a six-month transitional period while CMS builds out the full-scale BALANCE Model, which will launch in January 2027 with broader coverage, value-based contracting with manufacturers, and integrated behavioral health support.

CMS estimates that approximately 3.4 million Medicare beneficiaries will be eligible for the Bridge program, though actual enrollment will depend on prescriber capacity and patient awareness.³

What Will It Cost? The $50/Month Breakdown

The headline number is $50 per month — that is the maximum amount a Medicare beneficiary will pay out of pocket for a covered GLP-1 medication under the Bridge program.⁴

To put that in perspective, these same medications cost $900 to $1,350 per month at retail price without insurance. Even with commercial insurance, many patients pay $150–$300/month after copays and deductibles. The $50 Bridge price represents savings of up to 96%.

Here is how the $50/month pricing works:

• Fixed copayment structure: The $50 monthly maximum applies regardless of which covered medication you take (Wegovy or Zepbound). This is a flat copay, not a percentage-based coinsurance.⁵
• No deductible applies: The Bridge program copayment is not subject to the Part D deductible. You pay $50 from month one.
• Manufacturer contribution: Both Novo Nordisk (Wegovy) and Eli Lilly (Zepbound) have agreed to provide significant rebates to CMS to make the $50 price point possible. The exact rebate amounts have not been disclosed but are estimated at 60–75% of list price.⁶
• No impact on catastrophic coverage: Bridge program costs do not count toward the Part D out-of-pocket maximum ($2,000 in 2026 under the Inflation Reduction Act).

Which Drugs Are Covered?

The Bridge program covers two FDA-approved anti-obesity medications:

What Is NOT Covered

The following medications are not included in the Bridge program:

• Ozempic (semaglutide 0.5mg/1mg/2mg) — FDA-approved for type 2 diabetes, not obesity. Medicare already covers Ozempic for its on-label diabetes indication under standard Part D. The Bridge program specifically covers anti-obesity medications.⁷
• Mounjaro (tirzepatide) — The diabetes-branded version of the same molecule as Zepbound. Like Ozempic, it is already covered for diabetes under Part D.
• Compounded semaglutide or tirzepatide — Only FDA-approved brand-name products are eligible. Compounded versions from 503A or 503B pharmacies are excluded.
• Rybelsus (oral semaglutide) — Currently only FDA-approved for diabetes, not obesity. Not included in the Bridge program.
• Saxenda (liraglutide) — An older GLP-1 obesity medication with less efficacy. Not included in the Bridge program.

Eligibility Requirements

To qualify for the Medicare GLP-1 Bridge program, you must meet all of the following criteria:⁸

1. Medicare Enrollment

You must be actively enrolled in a Medicare Part D prescription drug plan (PDP) or a Medicare Advantage plan with prescription drug coverage (MA-PD) for the 2026 plan year. Original Medicare alone (Parts A and B) does not include drug coverage and is not sufficient.

If you are currently enrolled in a Part D plan, you do not need to switch plans. All Part D PDPs and MA-PDs are required to participate in the Bridge program.⁹

2. Clinical Criteria (BMI and Diagnosis)

You must have a clinical indication for anti-obesity medication, which generally means:

• BMI of 30 or greater (clinical obesity), OR
• BMI of 27 or greater with at least one weight-related comorbidity (such as type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease)

These are the same FDA-label criteria that apply to Wegovy and Zepbound prescriptions generally. Your prescribing physician will need to document these criteria.

3. Prescriber Requirements

The prescription must come from a qualified healthcare provider — typically a physician (MD/DO), nurse practitioner, or physician assistant authorized to prescribe in your state. CMS has not imposed additional prescriber restrictions beyond standard state scope-of-practice rules.¹⁰

Telehealth prescriptions are permitted. If you are already seeing a telehealth GLP-1 provider, they can write a prescription that qualifies for Bridge program coverage, as long as they accept Medicare.

Who Is NOT Eligible

• Beneficiaries enrolled in Original Medicare without Part D
• Individuals under 65 with Medicare due to disability who do not have Part D
• People enrolled in Medicaid but not Medicare (Medicaid has separate rules by state)
• Those who do not meet the BMI clinical criteria
• Beneficiaries in the Medicare Savings Program may have different cost-sharing — check with your plan

Step-by-Step: How to Enroll in the Bridge Program

The good news: there is no separate enrollment process for the Bridge program. If you meet the criteria above, coverage is automatic through your existing Part D plan. Here is what you need to do:

BMI Requirements & Prior Authorization Deep Dive

The prior authorization process is where many people get tripped up. Here is what to expect and how to prepare.

What Your Plan Will Review

When your doctor submits a prior authorization, the Part D plan will typically verify:

• Your BMI qualifies (30+ or 27+ with comorbidity)
• The diagnosis is documented in medical records
• The prescriber is a qualified, Medicare-enrolled provider
• The specific medication requested (Wegovy or Zepbound) is on the plan formulary for the Bridge program

CMS Guidance on Streamlined Authorization

CMS issued guidance in its March 2026 final rule directing Part D plans to implement "streamlined prior authorization" for Bridge program medications.¹¹ This means:

• Plans cannot impose step therapy requirements (e.g., requiring you try a cheaper drug first)
• Plans cannot require a minimum number of supervised diet attempts before approval
• Authorization decisions must be made within 72 hours for standard requests and 24 hours for expedited requests
• Initial authorization must cover the full titration and maintenance period through December 31, 2026

If Your Prior Authorization Is Denied

If your plan denies the prior authorization, you have the right to appeal. The appeals process is:

1. Coverage determination redetermination — Request a review by your plan (7 days for standard, 72 hours for expedited)
2. Independent Review Entity (IRE) — If the plan upholds the denial, an independent body reviews the case
3. Administrative Law Judge (ALJ) hearing — For amounts over $190 (2026 threshold)

CMS has indicated that denial rates for Bridge program medications should be low given the streamlined criteria, but early months may see processing delays as plans build out their systems.¹²

What Comes After the Bridge: The BALANCE Model (January 2027)

The Bridge program is explicitly temporary — it ends December 31, 2026. But it is not the end of Medicare GLP-1 coverage. On the contrary, it is the beginning.

Starting January 1, 2027, CMS will launch the BALANCE Model(Beneficiary Access to Leveraged Anti-obesity and Nutrition Care for Equity). This is the full, permanent framework for Medicare anti-obesity medication coverage.¹³

How BALANCE Differs from the Bridge

• Duration: BALANCE is a 10-year model (2027–2036), not a 6-month transition. It provides long-term coverage certainty.
• Broader drug coverage: While Bridge covers only Wegovy and Zepbound, BALANCE may include additional anti-obesity medications as they receive FDA approval (such as oral semaglutide for obesity, survodutide, or retatrutide).
• Value-based contracting: Manufacturers participating in BALANCE must agree to outcome-based rebates. If patients do not achieve specified weight loss thresholds, manufacturers refund a portion of the drug cost to Medicare.¹⁴
• Integrated behavioral support: BALANCE requires participating beneficiaries to have access to nutritional counseling and physical activity support, either through their provider or through a CMS-approved digital health program.
• Cost to patient:The $50/month copay from the Bridge program has not been confirmed for BALANCE. CMS has indicated that cost-sharing will be "affordable" but specific amounts are still under negotiation as of March 2026.

Cost Comparison: Bridge vs. Out-of-Pocket vs. Commercial Insurance

To understand just how significant the Bridge program pricing is, here is a side-by-side comparison of what you would pay for GLP-1 weight loss medication under different coverage scenarios.

The Bridge program is unambiguously the lowest-cost option for Medicare beneficiaries. Even compared to the best commercial insurance plans, $50/month is competitive. And compared to cash pay — where many seniors have been spending $1,000+ per month — the savings are life-changing.

Note that manufacturer savings cards are generally not available to Medicare beneficiaries. Federal anti-kickback statutes prohibit manufacturers from subsidizing Medicare copays in most circumstances.¹⁶ The Bridge program effectively replaces what savings cards do for commercially insured patients.

What to Do Right Now to Prepare

The Bridge program launches July 1, 2026 — just three months away. Here are the concrete steps you should take today to be ready.

Frequently Asked Questions